Pasithea Therapeutics Corp. Common Stock (KTTA) is a publicly traded Healthcare sector company. As of June 15, 2026, KTTA trades at $0.60 with a market cap of $19.75M and a P/E ratio of -0.20. KTTA moved +0.66% today. Year to date, KTTA is -54.18%; over the trailing twelve months it is -28.71%. Its 52-week range spans $0.28 to $4.39. Analyst consensus is buy with an average price target of $3.00. Rallies surfaces KTTA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Pasithea Therapeutics Corp. Common Stock (KTTA) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. KTTA moved +0.66% today. Analyst consensus is buy.
| Metric | Value |
|---|---|
| Price | $0.60 |
| Market Cap | $19.75M |
| P/E Ratio | -0.20 |
| EPS | $-2.91 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.39 |
| 52-Week Low | $0.28 |
| Volume | 1.24K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-20.43M |
| Gross Margin | 0.00% |
1 analysts cover KTTA: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.00.